Adherex Technologies (NASDAQ:FENC - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at B. Riley Financial in a research note issued on Monday, Benzinga reports. They presently have a $19.00 price target on the stock, up from their prior price target of $18.00. B. Riley Financial's target price suggests a potential upside of 63.51% from the company's current price.
FENC has been the subject of a number of other research reports. Zacks Research upgraded shares of Adherex Technologies from a "hold" rating to a "strong-buy" rating in a report on Thursday. Weiss Ratings upgraded Adherex Technologies from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday. HC Wainwright reiterated a "buy" rating and issued a $16.00 price objective on shares of Adherex Technologies in a report on Wednesday, September 9th. Finally, Wedbush upped their price target on Adherex Technologies from $13.00 to $16.00 and gave the company an "outperform" rating in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $17.25.
Read Our Latest Analysis on FENC
Adherex Technologies Price Performance
Shares of FENC opened at $11.62 on Monday. Adherex Technologies has a 52-week low of $5.65 and a 52-week high of $13.25. The stock has a fifty day simple moving average of $10.64 and a two-hundred day simple moving average of $9.36. The company has a market capitalization of $409.26 million, a PE ratio of 1,162.00 and a beta of 1.29.
Adherex Technologies (NASDAQ:FENC - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.02. Adherex Technologies had a net margin of 2.52% and a return on equity of 8.96%. The firm had revenue of $19.61 million for the quarter, compared to analysts' expectations of $18.87 million. As a group, equities analysts anticipate that Adherex Technologies will post 0.32 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Pierre Sargis Sayad sold 12,000 shares of Adherex Technologies stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $12.18, for a total transaction of $146,160.00. Following the sale, the insider owned 9,519 shares in the company, valued at approximately $115,941.42. The trade was a 55.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robert Andrade sold 75,000 shares of Adherex Technologies stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $11.78, for a total value of $883,500.00. Following the sale, the chief financial officer owned 217,675 shares in the company, valued at $2,564,211.50. This trade represents a 25.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.73% of the company's stock.
Adherex Technologies Company Profile
(
Get Free Report)
Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Adherex Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adherex Technologies wasn't on the list.
While Adherex Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.